Healthcare Industry Leader Virginia Rybski Remembered
Recognized compassionate pioneer loses her battle with pancreatic cancer
SCOTTSDALE, Ariz., May 13, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that CEO Virginia Rybski lost her battle with pancreatic cancer. Virginia was compassionately dedicated to her family, colleagues, patients and faith.
"We celebrate the privilege to have worked with such a talented leader, who was the driving force behind Regenesis' success," said John Voris, Chairman of the Board of Directors. "Virginia's legacy includes a capable and dedicated management team that remains intact. They are committed to achieving her vision of reaching patients in need of pain relief with the Provant® Therapy System."
Ms. Rybski served Regenesis most recently as President, Chief Executive Officer and Board Director. She combined 35 years experience founding and building emerging bioscience companies, by developing and commercializing numerous advanced-technology healthcare products. Virginia earned a Bachelor of Arts in Molecular Biology from the University of North Carolina, and a Masters in Hospital Administration from the University of Phoenix. She served on the Board of Directors for AdvaMed, the advanced medical technology association, as well as serving on the Emerging Growth Company Council, the Payment Advisory Work Group, and the Wound Sector Group. She also served on the Board of Directors for AZBIO, the Arizona biotechnology and medical device association.
Virginia is survived by her husband Tom, and daughters Savannah and Olivia. Her family provided the opportunity to support pancreatic research, through the Pancreatic Cancer Action Network at https://netcommunity.pancan.org/sslpage.aspx?pid=218
Regenesis will soon make an announcement regarding the CEO succession plan.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and outpatient clinics.
About the Provant® Therapy System
Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.
Contact: Regenesis Biomedical, Inc.
Scott Robey, Vice President Marketing
SOURCE Regenesis Biomedical, Inc.
More by this Source
FDA Clears the Provant Therapy System for Use by Patients with Metallic Implants
Dec 18, 2013, 13:51 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.